JAMA Viewpoint warns peptide compounding vote threatens the FDA approval system

Three researchers at the Center for Science in the Public Interest have warned in JAMA that peptide compounding could weaken the US drug approval system. Their Viewpoint, published online on October 26, responds to a July vote by an FDA advisory committee that backed six of seven unapproved peptides for the list of substances pharmacists may compound. The committee's votes are not binding. The FDA has not said whether it will start the rulemaking needed to put any of the peptides on that list.

What the JAMA Viewpoint argues

The Viewpoint is by Sophia Samantaroy, Isabella Xu and Peter Lurie, all of the Center for Science in the Public Interest in Washington. It frames the committee's recommendation as a threat both to the drug approval process and to patients. The authors note that the peptides are already widely sold online with labels saying they are for research use only, and they write that there is scant evidence that relevant research is being generated. Their concern is structural. A substance placed on the compounding list can reach patients through pharmacies on an individual prescription, without the controlled trials, manufacturing review and labeling that a new drug application requires. The full text is paywalled, so this report draws on the JAMA summary and opening sections.

Section 503A of the federal drug law sets the terms. A pharmacist may compound a drug for an individual patient from a bulk substance only if that substance is part of an FDA approved drug, is covered by a United States Pharmacopeia monograph, or has been added to the 503A Bulks List after an advisory committee meeting and a rulemaking. According to the Viewpoint, none of the seven peptides meets either of the first two conditions. The list is therefore the only lawful route for them under 503A. That is why the July vote drew attention well beyond pharmacy circles. It is a formal step toward a licensed supply of these peptides without any company first proving safety and efficacy to the agency.

How the advisory committee voted

The Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, at the FDA campus in Silver Spring, Maryland, under docket FDA-2025-N-6895. The agenda on the FDA meeting page shows that the first day covered BPC 157, KPV, TB 500 and MOTS c. The second day covered emideltide, also known as DSIP, together with semax and epitalon. Each was nominated for specific medical uses, from ulcerative colitis for BPC 157 to insomnia for epitalon. Healio reported the tallies. BPC 157, KPV and TB 500 each passed by eight votes to six with one abstention. MOTS c passed seven to five. Semax and epitalon also passed, while emideltide failed by six votes to seven.

BPC 157, KPV and TB 500 each passed by eight votes to six with one abstention.

Agency scientists argued against the listings. ABC News reported that FDA staff pointed to a general lack of quality data on safety and effectiveness, and Healio reported that staff reviewers recommended against all seven compounds. For TB 500, a physician who followed the meeting told Healio that reviewers could not identify a single human clinical study. Members who voted yes judged the risks to be minimal, ABC News reported, while those who voted no worried that compounding would give a false impression that the peptides had been tested to the standard of an approved drug. The votes are advice only. The FDA must review the record and decide whether to propose rules for any of the six peptides.

Seven peptides and the evidence gap

None of the seven peptides is an approved medicine in the United States, and the uses put before the committee were medical claims rather than wellness goals. The FDA agenda lists ulcerative colitis for BPC 157, wound healing and inflammatory conditions for KPV, wound healing for TB 500, and obesity and osteoporosis for MOTS c. Emideltide was nominated for opioid withdrawal, chronic insomnia and narcolepsy, semax for cerebral ischemia, migraine and trigeminal neuralgia, and epitalon for insomnia. The Viewpoint points out that the same compounds are already marketed online as research products. That label says the material is not meant for human use, and the authors describe the online trade as wide.

The evidence gap is the core of the dispute. A recommendation for the bulks list is not a finding that a peptide works. It only means the committee would accept pharmacies compounding it for a patient with a prescription. Compounded drugs are not FDA approved, so the agency does not review them for safety, effectiveness or quality before they are dispensed. The JAMA authors argue that if peptide compounding can deliver unproven substances to patients this way, companies have less reason to run the trials that approval demands. They also warn of harm to patients, since a pharmacy product can look like a regulated medicine while the evidence behind it remains thin and largely untested in people.

What happens next for peptide compounding

Nothing changes for patients or pharmacies yet. The committee's role is advisory, and the FDA page for the meeting states that advisory committees make nonbinding recommendations. To add a substance to the 503A list, the agency must publish a proposal, take public comment and issue a final rule. Until then, the peptides remain outside the lawful compounding routes described in the Viewpoint. The FDA has not announced a timetable. Healio reported that rulemaking is expected to stretch into 2027, and a physician quoted there said the agency does not have to accept the advice quickly or at all. For readers following peptide compounding, the next signal is a proposed rule in the Federal Register.

The debate also tests how far the agency will let the compounding route stretch for substances with thin evidence. Supporters of the vote, as ABC News described them, judged the risks to be minimal. The JAMA authors see a precedent that could let other unapproved compounds skip the approval pathway altogether. Our safety desk tracks compounding rules and the unapproved peptide market, and every agency step on these files will be logged there. The regulators desk covers formal decisions as they are published. Any proposed rule, comment period or final decision on the seven peptides will be reported with the primary documents linked, so readers can check each step for themselves.

Conclusion

The JAMA Viewpoint adds a public health voice to a decision the FDA has not yet made. Six of seven peptides won narrow committee backing in July, but no rule has been proposed and none of the compounds is approved. The authors argue that peptide compounding on this basis would bypass the evidence the approval system exists to demand. Readers should treat the July votes as advice, not permission, and can see our editorial standards for how we report on unapproved compounds.